Mostrar el registro sencillo del ítem

dc.contributor.authorNuñez Carro, Carmen*
dc.contributor.authorBlanco Blanco, Margarita*
dc.contributor.authorVillagrán Andrade, Karla Maurixi*
dc.contributor.authorBlanco García, Francisco*
dc.contributor.authorDe Andrés González, Mª Carmen*
dc.date.accessioned2025-09-09T11:23:38Z
dc.date.available2025-09-09T11:23:38Z
dc.date.issued2023
dc.identifier.citationNúñez-Carro C, Blanco-Blanco M, Villagrán-Andrade KM, Blanco FJ, de Andrés MC. Epigenetics as a Therapeutic Target in Osteoarthritis. Pharmaceuticals. MDPI; 2023;16(2).
dc.identifier.issn1424-8247
dc.identifier.otherhttps://portalcientifico.sergas.gal//documentos/640d5e77f0c92964f843ea4f
dc.identifier.urihttp://hdl.handle.net/20.500.11940/21519
dc.description.abstractOsteoarthritis (OA) is a heterogenous, complex disease affecting the integrity of diarthrodial joints that, despite its high prevalence worldwide, lacks effective treatment. In recent years it has been discovered that epigenetics may play an important role in OA. Our objective is to review the current knowledge of the three classical epigenetic mechanisms-DNA methylation, histone post-translational modifications (PTMs), and non-coding RNA (ncRNA) modifications, including microRNAs (miRNAs), circular RNAs (circRNAs), and long non-coding RNAs (lncRNAs)-in relation to the pathogenesis of OA and focusing on articular cartilage. The search for updated literature was carried out in the PubMed database. Evidence shows that dysregulation of numerous essential cartilage molecules is caused by aberrant epigenetic regulatory mechanisms, and it contributes to the development and progression of OA. This offers the opportunity to consider new candidates as therapeutic targets with the potential to attenuate OA or to be used as novel biomarkers of the disease.
dc.description.sponsorshipThis study has been funded by Instituto de Salud Carlos III (ISCIII) through the project PI19/01213 and co-funded by the European Union, and grants IN607D2022/12 and IN607A 2021/7 from Xunta de Galicia, Axencia Galega de Innovacion GAIN. M.C.D.A is supported by the Miguel Servet program from Fondo Investigacion Sanitaria-Spain (CP18/00084).
dc.languageeng
dc.rightsAttribution 4.0 International (CC BY 4.0)*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleEpigenetics as a Therapeutic Target in Osteoarthritis
dc.typeArtigo
dc.authorsophosNúñez-Carro, C.; Blanco-Blanco, M.; Villagrán-Andrade, K.M.; Blanco, F.J.; de Andrés, M.C.
dc.identifier.doi10.3390/ph16020156
dc.identifier.sophos640d5e77f0c92964f843ea4f
dc.issue.number2
dc.journal.titlePharmaceuticals*
dc.organizationInstituto de Investigación Biomédica de A Coruña (INIBIC)
dc.organizationComplexo Hospitalario Universitario A Coruña
dc.organizationComplexo Hospitalario Universitario A Coruña
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Complexo Hospitalario Universitario A Coruña::Reumatoloxía
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Instituto de Investigación Biomédica de A Coruña (INIBIC)::Unidade de investigación
dc.relation.projectIDInstituto de Salud Carlos III (ISCIII) [PI19/01213]
dc.relation.projectIDEuropean Union [IN607D2022/12, IN607A 2021/7]
dc.relation.projectIDXunta de Galicia, Axencia Galega de Innovacion GAIN
dc.relation.projectIDMiguel Servet program from Fondo Investigacion Sanitaria-Spain [CP18/00084]
dc.relation.publisherversionhttps://doi.org/10.3390/ph16020156
dc.rights.accessRightsopenAccess*
dc.subject.keywordINIBIC
dc.subject.keywordCHUAC
dc.subject.keywordCHUAC
dc.subject.keywordAS A Coruña
dc.subject.keywordCHUAC
dc.subject.keywordAS A Coruña
dc.subject.keywordINIBIC
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)
dc.typesophosArtículo de Revisión
dc.volume.number16


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution 4.0 International (CC BY 4.0)
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution 4.0 International (CC BY 4.0)